Business Context and Reporting Period
Company: Ascentage Pharma Group International
Filing Type: Form 6-K (Report of Foreign Private Issuer)
Reporting Period: Month of July 2026
Date of Filing: July 20, 2026
Principal Executive Offices: 68 Xinqing Road, Suzhou Industrial Park, Suzhou, Jiangsu, China
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report is a regulatory disclosure regarding a corporate action rather than a financial results statement.
Material Changes
On July 19, 2026, the Company issued a Voluntary Announcement and Overseas Regulatory Announcement titled "Proposed At-The-Market Offering Program Pursuant to a Registration Statement on Form F-3 Filed with The U.S. Securities And Exchange Commission and Application for Waivers from the Listing Rules."
Guidance, Outlook, and Risks
Management Commentary: The Company is proposing an At-The-Market (ATM) Offering Program under a Form F-3 registration statement.
Regulatory Actions: The Company has applied for waivers from the Listing Rules associated with this offering program.
Risks and Contingencies: The filing text does not explicitly detail specific risks or contingencies beyond the regulatory nature of the proposed offering.
Investor Verification Checklist
- Review the full text of the Voluntary Announcement (Exhibit 99.1) for details on the proposed ATM Offering Program.
- Verify the status of the Form F-3 Registration Statement with the SEC.
- Confirm the outcome of the application for waivers from the Listing Rules.
- Assess the potential dilution impact of the proposed offering on existing shareholders.